Browse By Person: Doggrell, Sheila

Group by: Item Type | Date

Number of items: 140.

Book

Doggrell, Sheila, Davis, Elizabeth, Hart, Joanne, Hinton, Tina, Johnson, Graham, & Mullaney, Ian (2012) Pharmacology in one semester. Sheila Doggrell.

Book Chapter

Doggrell, Sheila & Davis, Elisabeth (2012) Anti-infectives. In Doggrell, Sheila (Ed.) Pharmacology in One semester.

Doggrell, Sheila (2012) Drug development. In Phamacology in one semester. Doggrell, Sheila.

Doggrell, Sheila (2012) Drug distribution, metabolism and elimination, and relationship to blood levels. In Doggrell, Sheila (Ed.) Pharmacology in one semester. eBook.

Doggrell, Sheila & Hart, Joaane L. (2012) Drugs Used to Treat Endocrine Disorders. In Doggrell, Sheila (Ed.) Pharmacology in One Semester.

Doggrell, Sheila (2012) Drugs and the autonomic nervous system. In Doggrell, Sheila (Ed.) Pharmacology in One Semester.

Doggrell, Sheila (2012) Drugs and the respiratory system. In Doggrell, Sheila (Ed.) Pharmacology in One Semester.

Doggrell, Sheila (2012) Introduction to pharmacology, and routes of drug administration. In Doggrell, Sheila (Ed.) Pharmacology in one semester. Sheila Doggrell.

Doggrell, Sheila (2012) Neurological drugs and opioids for pain management. In Doggrell, Sheila (Ed.) Pharmacology in One semester.

Doggrell, Sheila (2012) Pharmacodynamics. In Doggrell, Sheila (Ed.) Pharmacology in one semester. Doggrell, Sheila.

Doggrell, Sheila (2012) Pharmacovigilance and pharmacogenetics. In Doggrell, Sheila (Ed.) Pharmacology in one semester. Doggrell, Sheila.

Doggrell, Sheila (2012) Poisoning with drugs. In Doggrell, Sheila (Ed.) Pharmacology in one semester. Doggrell, Sheila.

Doggrell, Sheila (2012) Smoking cessation. In Doggrell, Sheila (Ed.) Pharmacology in One Semester.

Journal Article

Doggrell, Sheila Anne & Chan, Vincent (2012) Bariatric surgery or medicine for type 2 diabetes? Expert Opinion on Pharmacotherapy, 13(15), pp. 2249-2253.

Doggrell, Sheila (2012) Dalcetrapib restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease. Expert Opinion in Investigational Drugs, 21(4), pp. 569-573.

Doggrell, Sheila & Kairuz, Therese (2012) Medicine management by the older-aged living independently in different types of retirement villages. Journal of Pharmacy Practice and Research, 42, pp. 208-212.

Doggrell, Sheila (2011) Adherence to oral endocrine treatments in women with breast cancer: can it be improved? Breast Cancer Research and Treatment, 129(2), pp. 299-308.

Doggrell, Sheila & Christensen, Anne-Marie (2011) Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Expert Opinion on Pharmacotherapy, 12(1), pp. 157-163.

Doggrell, Sheila (2011) Bitter taste receptors as a target for bronchodilation. Expert Opinion on Therapeutic Targets, 15(7), pp. 899-902.

Doggrell, Sheila (2011) CX3CR1 as a target for airways inflammation. Expert Opinion on Therapeutic Targets, 15(9), pp. 1139-1142.

Doggrell, Sheila (2011) Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease? Reviews on Recent Clinical Trials, 6(2), pp. 147-157.

Doggrell, Sheila (2011) Lemur tyrosine kinase-3 (LMTK3) as a target in oestrogen positive breast cancer. Expert Opinion on Therapeutic Targets, 15(12), pp. 1419-1422.

Doggrell, Sheila (2011) Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: Is it still relevant in 2011? Complementary Therapies in Medicine, 19(1), pp. 37-46.

Doggrell, Sheila (2011) Sitagliptin or exenatide once weekly for type 2 diabetes: Comparison of the clinical trials. Expert Opinion on Pharmacotherapy, 12(13), pp. 2055-2067.

Doggrell, Sheila (2011) Treatment for relapsed Hodgkin lymphoma: Refinement of chemotherapy or targeted treatment? Expert Opinion on Pharmacotherapy, 12(6), pp. 991-994.

Doggrell, Sheila (2011) A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2. Expert Opinion on Investigational Drugs: authoritative analysis of R&D trends, 20(4), pp. 587-590.

Doggrell, Sheila Anne (2010) Resolvin inflammation with pain. Expert Opinion on Investigational Drugs, 19(11), pp. 1461-1464.

Doggrell, Sheila Anne (2010) Oral fingolimod for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 11(10), pp. 1777-1781.

Doggrell, Sheila (2010) Zoledronic acid once-yearly : what role in the prevention of non-vertebral osteoporotic fractures? Clinical Medicine Insights: Therapeutics, 2010(2), pp. 539-547.

133

Doggrell, Sheila Anne (2010) The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers. Expert Opinion on Investigational Drugs, 19(3), pp. 451-454.

107

Doggrell, Sheila (2010) Adherence to medicines in the older-aged with chronic conditions : does an intervention concerning adherence by an allied health professional help? Drugs and Aging, 27(3), pp. 239-254.

408

Doggrell, Sheila (2010) Does intervention by an allied health professional discussing adherence to medicines improve this adherence in Type 2 diabetes? Diabetic Medicine: journal of diabetes UK, 27(12), pp. 1341-1349.

Doggrell, Sheila Anne & Christensen, Anne-Marie (2010) Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis? Expert Opinion on Pharmacotherapy, 11(14), pp. 2437-2442.

Doggrell, Sheila (2010) Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer. Expert Opinion on Pharmacotherapy, 11(7), pp. 1225-1230.

Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes. Expert Opinion on Pharmacotherapy, 11(2), pp. 325-329.

Hancox, Jules & Doggrell, Sheila (2010) Perspective: Does ranolazine have potential for the treatment of atrial fibrillation? Expert Opinion on Investigational Drugs, 19(12), pp. 1465-1474.

Doggrell, Sheila (2009) Is liraglutide or exenatide better in type 2 diabetes? Expert Opinion on Pharmacotherapy, 10(16), pp. 2769-2772.

222

Doggrell, Sheila (2009) Anti-cancer activity of zoledronic acid in breast cancer. Expert Opinion on Pharmacotherapy, 10(14), pp. 2387-2390.

Doggrell, Sheila (2009) Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget's disease. Expert Review of Endocrinology and Metabolism, 4(5), pp. 405-415.

Doggrell, Sheila (2009) Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Review of Anticancer Therapy, 9(9), pp. 1211-1218.

156

Doggrell, Sheila (2009) Good clinical endpoints with denosumab in osteoporosis and cancer. Expert Opinion in Pharmacotherapy, 10(17), pp. 2939-2943.

100

Doggrell, Sheila (2009) Lyprinol : is it a useful anti-inflammatory agent? Evidence Based Complementary and Alternative Medicine.

253

Doggrell, Sheila (2009) New findings with old drugs for osteoporosis. Expert Opinion on Pharmacotherapy, 10(3), pp. 513-516.

103

Doggrell, Sheila (2009) Telcagepant is a new oral treatment for migraine. Expert Opinion in Pharmacotherapy, 10(9), pp. 1523-1526.

115

Doggrell, Sheila (2009) Tesofensine : a novel potent weight loss medicine. Expert Opinion in Investigational Drugs, 18(7), pp. 1043-1046.

122

Doggrell, Sheila (2009) Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes. IDrugs, 12(5), pp. 309-317.

Doggrell, Sheila (2008) What is the future for rimonabant in the treatment of obesity. Review of Endocrinology, December, pp. 14-17.

Doggrell, Sheila (2008) Celecoxib to prevent restenosis - results from the COREA-TAXUS trial. Expert Opinion on Pharmacotherapy, 9(2), pp. 339-341.

Doggrell, Sheila (2008) Clinical trials with thiazolidinediones in subjects with Type 2 diabetes - is pioglitazone any different from rosiglitazone? Expert Opinion on Pharmacotherapy, 9(3), pp. 405-420.

Doggrell, Sheila (2008) Is long-term adjuvant treatment of breast cancer with anastrozole indicated? Expert Opinion on Pharmacotherapy, 9(9), pp. 1619-1622.

Doggrell, Sheila (2008) Is rimonabant efficacious and safe in the treatment of obesity? Expert Opinion on Pharmacotherapy, 9(15), pp. 2727-2731.

Doggrell, Sheila (2008) Is sapropterin treatment suitable for all subjects with phenylketonuria? Expert Opinion on Pharmacotherapy, 9(1), pp. 145-147.

Doggrell, Sheila (2008) Is tocilizumab an option for the treatment of arthritis? Expert Opinion on Pharmacotherapy, 9(11), pp. 2009-2013.

Doggrell, Sheila (2008) New horizons for zoledronic acid: results of the HORIZON trials in postmenopausal women with osteoporosis and after hip fracture. Expert Opinion on Pharmacotherapy, 9(4), pp. 663-668.

Doggrell, Sheila (2008) New indications for topiramate: alcohol dependency and binge-eating disorder. Expert Opinion on Pharmacotherapy, 9(5), pp. 869-873.

Doggrell, Sheila (2008) Therapeutic potential of non-peptide chymase inhibitors. Expert Opinion on Therapeutic Patents, 18(5), pp. 485-499.

Doggrell, Sheila (2007) Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target? Current Opinion in Investigational Drugs, 8(9), pp. 742-749.

Doggrell, Sheila (2007) Clopidogrel use with stenting. Expert Opinion on Pharmacotherapy, 8(9), pp. 1399-1402.

Doggrell, Sheila (2007) Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? International Journal of Impotence Research, 19(3), pp. 281-295.

Doggrell, Sheila (2007) Does rosiglitazone increase cardiovascular outcomes? Expert Opinion on Pharmacotherapy, 8(15), pp. 2665-2669.

Doggrell, Sheila (2007) Is fingolimod an advancement in the treatment of multiple sclerosis? Expert Opinion on Pharmacotherapy, 8(3), pp. 383-386.

Doggrell, Sheila (2007) Misoprostol for the treatment of early pregnancy failure. Current Clinical Pharmacology, 2(1), pp. 1-9.

Doggrell, Sheila (2007) New drugs and new targets down under in 2006: highlights from the 3rd Australian Health and Medical Research Congress. Drugs of the Future, 32(1), pp. 93-102.

Doggrell, Sheila (2007) Novel drugs and products in neuroscience: highlights from IBRO. Drugs of the Future, 32(11), pp. 1007-1017.

Doggrell, Sheila (2007) Rosiglitazone: rosy news for a thiazolidinedione. Expert Opinion on Pharmacotherapy, 8(2), pp. 265-268.

Doggrell, Sheila (2007) Which is the best primary medication for long-term smoking cessation - nicotine replacement therapy, bupropion or varenicline? Expert Opinion on Pharmacotherapy, 8(17), pp. 2903-2915.

Doggrell, Sheila (2006) After the failure of citalopram for depression, what next? Expert Opinion on Pharmacotherapy, 7(11), pp. 1515-1518.

Doggrell, Sheila (2006) Bradykinin B2 receptors as a target in diabetic nephropathy. Current Opinion in Investigational Drugs, 7(3), pp. 251-255.

Doggrell, Sheila (2006) Ceramide as a target in emphysema. Expert Opinion on Therapeutic Targets, 10(1), pp. 191-194.

Doggrell, Sheila (2006) Inhibition of RANKL: a new approach to the treatment of osteoporosis. Expert Opinion on Pharmacotherapy, 7(8), pp. 1097-1100.

Doggrell, Sheila (2006) Inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. Expert Opinion on Investigational Drugs, 15(2), pp. 99-106.

Doggrell, Sheila (2006) Is NXY-059 an advancement in the treatment of acute ischaemic stroke? Expert Opinion on Pharmacotherapy, 7(7), pp. 965-968.

Doggrell, Sheila (2006) Is amlodipine the best initial monotherapy for hypertension? Expert Opinion on Pharmacotherapy, 7(6), pp. 829-832.

Doggrell, Sheila (2006) Is exenatide advancing the treatment of Type 2 diabetes? Expert Opinion on Pharmacotherapy, 7(1), pp. 109-112.

Doggrell, Sheila (2006) Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes? Expert Opinion on Pharmacotherapy, 7(9), pp. 1229-1233.

Doggrell, Sheila (2006) Natalizumab in multiple sclerosis: proceed with caution? Expert Opinion on Pharmacotherapy, 7(12), pp. 1675-1678.

Doggrell, Sheila (2006) New targets in and potential treatments for cholesterol gallstone disease. Current Opinion in Investigational Drugs, 7(4), pp. 344-348.

Doggrell, Sheila (2006) Nitrone spin on cerebral ischemia. Current Opinion in Investigational Drugs, 7(1), pp. 20-24.

Doggrell, Sheila (2006) Partial agonism at nicotinic receptors with varenicline - a new approach to smoking cessation. Expert Opinion on Pharmacotherapy, 7(18), pp. 2599-2603.

Doggrell, Sheila (2006) Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease. Expert Opinion on Pharmacotherapy, 7(4), pp. 485-488.

Doggrell, Sheila (2006) Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus. Expert Opinion on Therapeutic Targets, 10(4), pp. 627-630.

Doggrell, Sheila (2006) Recent evidence of sustained benefit with exenatide in Type 2 diabetes. Expert Opinion on Pharmacotherapy, 7(14), pp. 2003-2006.

Doggrell, Sheila (2006) Sibutramine for obesity in adolescents. Expert Opinion on Pharmacotherapy, 7(17), pp. 2435-2438.

Doggrell, Sheila (2006) 'Simply stunning' - trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy, 7(5), pp. 631-634.

Doggrell, Sheila (2006) Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation. Expert Opinion on Pharmacotherapy, 7(2), pp. 225-228.

Doggrell, Sheila (2006) Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention? Expert Opinion on Pharmacotherapy, 7(15), pp. 2169-2173.

Doggrell, Sheila (2005) Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding. Expert Opinion on Pharmacotherapy, 6(7), pp. 1253-1256.

Doggrell, Sheila (2005) BG-9928 (Biogen Idec). Current Opinion in Investigational Drugs, 6(9), pp. 962-968.

Doggrell, Sheila (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opinion on Investigational Drugs, 14(1), pp. 89-91.

Doggrell, Sheila (2005) Berberine - a novel approach to cholesterol lowering. Expert Opinion on Investigational Drugs, 14(5), pp. 683-685.

Doggrell, Sheila (2005) Bradykinin B2 receptors - a target in diabetic nephropathy. Expert Opinion on Therapeutic Targets, 9(2), pp. 411-414.

Doggrell, Sheila (2005) CHARMed - the effects of candesartan in heart failure. Expert Opinion on Pharmacotherapy, 6(3), pp. 513-516.

Doggrell, Sheila (2005) CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. Expert Opinion on Pharmacotherapy, 6(10), pp. 1761-1764.

Doggrell, Sheila (2005) Calmodulin kinase II as a target for inhibition in cardiac disease. Expert Opinion on Therapeutic Targets, 9(6), pp. 1319-1321.

Doggrell, Sheila & Wanstall, Janet (2005) Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Canadian Journal of Physiology and Pharmacology, 83(2), pp. 123-130.

Doggrell, Sheila (2005) Clinical evidence for drug treatments in obesity in hypertensive patients. Methods and Findings in Experimental and Clinical Pharmacology, 27(2), pp. 119-125.

Doggrell, Sheila (2005) Clinical potential of nitric oxide-independent soluble guanylate cyclase activators. Current Opinion in Investigational Drugs, 6(9), pp. 874-878.

Doggrell, Sheila (2005) Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opinion on Pharmacotherapy, 6(1), pp. 75-84.

Doggrell, Sheila (2005) Conivaptan (Yamanouchi). Current Opinion in Investigational Drugs, 6(3), pp. 317-326.

Doggrell, Sheila (2005) Cytochrome P-450: a new target in the heart and coronary circulation. Drugs of the Future, 30(3), pp. 261-269.

Wanstall, Janet, Homer, Kerry, & Doggrell, Sheila (2005) Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Current Vascular Pharmacology, 3(1), pp. 41-53.

Doggrell, Sheila (2005) Farnesoid X receptor agonism - a new approach to the treatment of cholesterol gallstone disease. Expert Opinion on Investigational Drugs, 14(4), pp. 535-538.

Doggrell, Sheila (2005) Fluoxetine - do the benefits outweigh the risks in adolescent major depression? Expert Opinion on Pharmacotherapy, 6(1), pp. 147-150.

Doggrell, Sheila (2005) Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved? Expert Opinion on Pharmacotherapy, 6(5), pp. 831-834.

Doggrell, Sheila & Hancox, Jules (2005) Ibutilide - recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opinion on Investigational Drugs, 14(5), pp. 655-669.

Doggrell, Sheila (2005) Inhibitors of cholesteryl ester transfer protein - a step forward in the treatment of coronary artery disease? Drugs of the Future, 30(1), pp. 45-50.

Doggrell, Sheila (2005) Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia? Expert Opinion on Investigational Drugs, 14(8), pp. 1063-1066.

Doggrell, Sheila (2005) Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity? Expert Opinion on Pharmacotherapy, 6(12), pp. 2141-2144.

Doggrell, Sheila (2005) More support for high-dose atorvastatin in coronary artery disease. Expert Opinion on Pharmacotherapy, 6(13), pp. 2365-2368.

Doggrell, Sheila (2005) NF-(kappa)B - a target in the inflammation of bone destruction. Expert Opinion on Therapeutic Targets, 9(1), pp. 191-193.

Doggrell, Sheila (2005) Neuromedin U - a new target in obesity. Expert Opinion on Therapeutic Targets, 9(4), pp. 875-877.

Doggrell, Sheila (2005) New drugs being developed for the treatment of tuberculosis. Expert Opinion on Investigational Drugs, 14(7), pp. 917-920.

Doggrell, Sheila (2005) Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration. Expert Opinion on Pharmacotherapy, 6(8), pp. 1421-1423.

Doggrell, Sheila (2005) Phosphodiesterase 5A as a target in cardiac disease. Expert Opinion on Therapeutic Targets, 9(5), pp. 1097-1100.

Doggrell, Sheila (2005) Potential of growth hormone-releasing hormone antagonists (JV-1-36 and JV-1-42) for the treatment of brain tumours. Expert Opinion on Investigational Drugs, 14(12), pp. 1561-1564.

Doggrell, Sheila (2005) Pregabalin or morphine and gabapentin for neuropathic pain. Expert Opinion on Pharmacotherapy, 6(14), pp. 2535-2539.

Doggrell, Sheila (2005) Recent findings with docetaxel in postoperative treatment for breast cancer. Expert Opinion on Pharmacotherapy, 6(16), pp. 2903-2906.

Doggrell, Sheila (2005) Recent important trials of pharmacotherapy in Parkinson's disease. Expert Opinion on Pharmacotherapy, 6(6), pp. 1025-1028.

Doggrell, Sheila (2005) Relating statin therapy to C-reactive protein levels. Expert Opinion on Pharmacotherapy, 6(9), pp. 1597-1600.

Doggrell, Sheila (2005) Rho-kinase inhibitors show promise in pulmonary hypertension. Expert Opinion on Investigational Drugs, 14(9), pp. 1157-1159.

Doggrell, Sheila (2005) Stabilisation of calstabin2 - a new approach in sudden cardiac death. Expert Opinion on Therapeutic Targets, 9(5), pp. 955-962.

Doggrell, Sheila (2005) Taking the 20-HETE out of the cardiovascular system: The potential of 20-HETE synthesis inhibitors. Current Opinion in Investigational Drugs, 6(9), pp. 901-906.

Doggrell, Sheila (2005) Which drug combination for hormone-refractory prostate cancer? Expert Opinion on Pharmacotherapy, 6(4), pp. 667-670.

Doggrell, Sheila (2005) Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Expert Opinion on Investigational Drugs, 14(3), pp. 339-342.

Doggrell, Sheila (2005) Ximelagatran - recent comparisons with warfarin. Expert Opinion on Pharmacotherapy, 6(11), pp. 1943-1946.

Doggrell, Sheila (2005) The nitrosterols - a step forward from the steroid anti-inflammatory drugs? Expert Opinion on Investigational Drugs, 14(7), pp. 823-828.

Doggrell, Sheila (2005) The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy, 6(2), pp. 347-350.

Doggrell, Sheila (2005) A small-molecule lead compound for the treatment of Alzheimer's disease. Expert Opinion on Investigational Drugs, 14(2), pp. 199-201.

Conference Item

Doggrell, Sheila Anne, Schaffer, Sally, & Dallemagne, Catherine (2012) Transferring a successful strategy for supporting accelerated nursing students from a small to a large cohort. In Nelson, Karen J. & Kift, Sally M. (Eds.) 15th International First Year in Higher Education Conference : New Horizons, 26-29 June 2012, Sofitel Brisbane Central, Brisbane, QLD.

Review

Doggrell, Sheila (2012) More light at the end of the tunnel – apixaban in atrial fibrillation. Expert Opinion in Investigational Drugs, 13(10), pp. 1470-1480.

Doggrell, Sheila & Hancox, Jules (2012) PALLAS : limiting indications for dronedarone treatment of atrial fibrillation. Expert Opinion on Pharmacotherapy, 13(6), pp. 1-5.

Doggrell, Sheila (2012) Apixaban for the prevention of thromboembolism in adults after elective hip or knee replacement surgery, and in symptomatic venous thromboembolism. Clinical Medicine Reviews in Vascular Health, 4, pp. 19-28.

Doggrell, Sheila (2012) The ezetimibe controversy? Can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opinion on Pharmacotherapy, 13(10), pp. 1469-1480.

Other

Doggrell, Sheila (2012) Drugs and local chemical mediators. Pharmacology in One Semester.

Doggrell, Sheila (2012) Drugs and neurotransmitters. Pharmacology in One Semester.

Doggrell, Sheila (2012) Drugs and the gastrointestinal tract. Pharmacology in One Semester. (Unpublished)

Doggrell, Sheila (2012) Drugs and the somatic nervous system. Pharmacology in One Semester.

Doggrell, Sheila (2012) Drugs for cardiac arrhythmmias, antithrombotic drugs and lipid modulating drugs. Pharmacology in one semester.

Doggrell, Sheila (2012) Drugs for diabetes and obesity. Pharmacology in one semester.

Doggrell, Sheila (2012) Drugs for hypertension, angina and heart failure. Pharmacology in One Semester.

This list was generated on Sat May 18 07:10:49 2013 EST.

Export as	RSS 1.0 Atom RSS 2.0